Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II-Renin Feedback in Hypertensive Patients.
Journal
International journal of hypertension
ISSN: 2090-0384
Titre abrégé: Int J Hypertens
Pays: United States
ID NLM: 101538881
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
11
2020
accepted:
10
12
2020
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
Cilnidipine, an L-/N-type calcium channel blocker (CCB), has unique organ-protective properties due to suppression of hyperactivity in the sympathetic nervous system and renin-angiotensin system (RAS). In this study, we hypothesized that cilnidipine might exert a renoprotective effect by suppressing the RAS. A total of 25 hypertensive patients receiving a RAS inhibitor were randomly assigned to a cilnidipine ( After 6 months of treatment, both systolic and diastolic blood pressures were significantly reduced to a similar extent in both groups. The urine albumin-to-creatinine ratio was significantly lower in the cilnidipine group ( The L-/N-type CCB cilnidipine, but not amlodipine, decreased urinary albumin excretion in hypertensive patients. Cilnidipine also increased the ratio of Ang-(1-7) to angiotensin II in plasma, which might be one factor underlying its beneficial effects.
Identifiants
pubmed: 33489354
doi: 10.1155/2020/6653851
pmc: PMC7803135
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6653851Informations de copyright
Copyright © 2020 Yutaka Kawabata et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest declare.
Références
Mini Rev Med Chem. 2006 May;6(5):603-9
pubmed: 16719835
Curr Hypertens Rep. 2014 Mar;16(3):420
pubmed: 24510672
Hypertens Res. 2011 Apr;34(4):521-9
pubmed: 21270815
Hypertension. 2008 Feb;51(2):574-80
pubmed: 18180400
J Mol Med (Berl). 2008 Jun;86(6):663-71
pubmed: 18437333
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042
Am J Physiol Heart Circ Physiol. 2007 Jan;292(1):H666-72
pubmed: 17213482
Heart Vessels. 2007 Nov;22(6):404-9
pubmed: 18043999
Hypertens Res. 1999 Nov;22(4):273-7
pubmed: 10580393
Hypertens Res. 1998 Sep;21(3):215-9
pubmed: 9786607
Br J Pharmacol. 1997 Sep;122(1):37-42
pubmed: 9298526
Hypertens Res. 2012 Nov;35(11):1058-62
pubmed: 22763473
Am J Nephrol. 2009;30(2):155-61
pubmed: 19325231
J Hypertens. 2010 May;28(5):1034-43
pubmed: 20411599
Am J Nephrol. 2008;28(1):25-33
pubmed: 17890855
Hypertens Res. 2007 Sep;30(9):815-22
pubmed: 18037774
Am J Physiol Renal Physiol. 2010 Jun;298(6):F1297-305
pubmed: 20375118
Br J Pharmacol. 2009 Nov;158(5):1366-74
pubmed: 19785655
Circulation. 2010 Aug 17;122(7):717-28, 18 p following 728
pubmed: 20679547
Am J Nephrol. 2011;33(2):168-75
pubmed: 21293118
Nephron Clin Pract. 2005;101(2):c47-52
pubmed: 15942250
Pharmacol Ther. 2015 Jul;151:1-7
pubmed: 25659931
Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):645-51
pubmed: 10712386
Indian J Nephrol. 2015 Nov-Dec;25(6):334-9
pubmed: 26664207
Kidney Int. 2007 Dec;72(12):1543-9
pubmed: 17943080
Exp Physiol. 2013 Jan;98(1):109-22
pubmed: 22750422
Eur J Pharmacol. 2002 Jan 2;434(1-2):43-7
pubmed: 11755164